• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
EYPT

EYPT

EyePoint Pharmaceuticals, Inc.

NASDAQHealthcareBiotechnologyUS

USD12.34

-0.19 (-1.52%)

Rating:C-

Company Profile

CEO

Jay S. Duker

IPO Date

2005-01-27

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$12.37

Prev. Close

$12.53

Day Low

$12.17

Day High

$12.51

52W Low

$7.94

52W High

$19.11

Market Cap

$1.03B

Volume

0.84M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

21.8%

Avg Negative

5.4%

Avg Neutral

72.9%

News Feed

EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021

GlobeNewsWire·7/28/2021·↑ positive

EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®

GlobeNewsWire·7/20/2021·↑ positive

EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical Association

GlobeNewsWire·7/1/2021·↑ positive

EyePoint Pharmaceuticals Joins Russell 2000® and Russell 3000® Index

GlobeNewsWire·6/28/2021·↑ positive

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/5/2021·↓ negative

EyePoint Pharmaceuticals's Earnings Outlook

Benzinga·5/4/2021·↓ negative

EyePoint Pharmaceuticals End Of Year Earnings Call Analysis

Seeking Alpha·4/22/2021·↓ negative

EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call Transcript

Seeking Alpha·3/4/2021·↓ negative

EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue Estimates

Zacks Investment Research·3/4/2021·↑ positive

EyePoint Pharmaceuticals: Time For Liftoff

Seeking Alpha·2/14/2021·↑ positive